GlassScriptPhysician profile
Daisy M Edwards
NPI 1083954846
$3,300.00
in general payments reported to CMS, 2019-2025
24 companies · $802 in 2025
The $802 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $571 · 2023: $881 · 2024: $617 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.03 | 2022-2025 | |
| Novo Nordisk INC | $572.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $470.48 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $240.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.28 | 2021-2024 | Trintellix |
| Amgen INC. | $169.77 | 2024-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.64 | 2021-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $134.97 | 2025 | Recorlev |
| Genzyme Corporation | $120.15 | 2023 | |
| Exact Sciences Corporation | $106.48 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $92.22 | 2023-2025 | Aristada, Vivitrol, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $45.73 | 2022-2025 | Eliquis |
| Abbott Laboratories | $39.43 | 2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $38.14 | 2024 | Fanapt, Hetlioz |
| Amarin Pharma, INC. | $36.56 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.83 | 2023 | Rexulti |
| Astellas Pharma US INC | $26.19 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.47 | 2023 | Spravato |
| Glaxosmithkline, LLC. | $18.85 | 2025 | Shingrix |
| Lilly USA, LLC | $15.98 | 2025 | Mounjaro |
| Lundbeck LLC | $15.30 | 2025 | Rexulti |
| Bioventus LLC | $15.27 | 2025 | Durolane |
| Currax Pharmaceuticals LLC | $15.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.